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Bloom’s syndrome is a rare autosomal recessive disorder charac-
terized phenotypically by retarded growth, sun sensitivity,
immuno-deficiency and predisposition to a wide variety of cancers
at an early age (German, 1993, 1995). This cancer predisposition
is of particular interest given that leukaemias, lymphomas and
epithelial cancers are all represented. Cells from affected individ-
uals show genetic instability, manifested as an elevated frequency
of chromosome breaks and aberrations, as well as the hallmark
feature of an approximately 10-fold elevation in the frequency of
reciprocal exchanges between sister-chromatids (SCEs) (German,
1993, 1995). The gene mutated in Bloom’s syndrome, BLM,
encodes a member of the RecQ family of DExH box-containing
DNA helicases (Ellis et al, 1995). Other RecQ family members
include Saccharomyces cerevisiae Sgs1p,  Schizosaccharomyces
pombe Rqh1p, and the RECQL, RECQ4, RECQ5 and WRN
proteins from human cells (reviewed in Chakraverty and Hickson,
1999; Karow et al, 2000a). Studies using either native or recombi-
nant proteins have indicated that these proteins are helicases that
unwind DNA in a 3¢–5¢ direction (Umezu and Nakayama, 1993;
Puranam and Blackshear, 1994; Seki et al, 1994; Gray et al, 1997;
Karow et al, 1997; Suzuki et al, 1997; Bennett et al, 1998; Shen 
et al, 1998). BLM is not the only member of the RecQ family to be
mutated in a human genetic disorder. The WRN gene is mutated in
the premature ageing disorder, Werner’s syndrome (Yu et al,
1996), in which individuals also have an elevated incidence of
cancer, particularly sarcomas. Moreover, the RecQ4 gene is
mutated in some cases of Rothmund-Thomson syndrome (Kitao 
et al, 1999), a rare disorder associated with skin and skeletal
abnormalities, some features of premature ageing, and a predispo-
sition to certain cancers. 
Cells from Bloom’s syndrome individuals show a variety of
defects in the maintenance of genome stability. In addition to an
elevated frequency of SCEs, Bloom’s syndrome cells have a
mutator phenotype and an elevated rate of genetic recombination
events between homologous sequences, including the formation of
quadriradial chromosomes (German, 1993, 1995). Although the
precise role of the BLM protein (or indeed of any of the RecQ
family helicases) in DNA metabolism remains to be elucidated,
many of these proteins appear to play roles in genetic recombina-
tion, particularly during DNA replication (Chakraverty and
Hickson, 1999). Consistent with such a role, the BLM protein has
been shown to interact physically and functionally with replication
protein A (RPA) (Brosh et al, 2000), and to bind selectively to the
Holliday junction recombination intermediate (Karow et al,
2000b). Indeed, BLM has been shown to promote efficient branch
migration of Holliday junctions (Karow et al, 2000b), suggesting a
possible role in the production of mature DNA recombinants
during repair of DNA damage. 
Previous studies using cultured cell lines have indicated that the
BLM protein is poorly expressed in non-proliferating cells and
peaks during S/G2-phases of the cell division cycle (Dutertre et al,
2000). Moreover, BLM protein has been shown to localize to the
nucleus and at certain stages of the cell cycle to be present both in
nucleoli and in PML nuclear bodies (Ishov et al, 1999; Zhong et al,
1999; Wu et al, 2000a, 2000b; Yankiwski et al, 2000). However
little is known about the expression of the BLM protein in cells
and tissues in vivo, or whether BLM is generally expressed in
human cancers. Using a specific anti-BLM antibody, which we
have validated previously using cell lines and recombinant
proteins (Wu et al, 2000a), we have characterized the expression
of BLM in normal and neoplastic tissues using immunohistochem-
istry. We show that BLM is a nuclear protein in human tissues and
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origin than in other normal tissues. In contrast, BLM is widely
expressed in tumour cells of both lymphoid and epithelial origin. 
MATERIALS AND METHODS 
Antibodies 
Generation of the BFL-103 antibody has been described previ-
ously (Wu et al, 2000a). The antigen used to raise this mouse
monoclonal antibody was full-length recombinant BLM expressed
in  Saccharomyces cerevisiae (Karow et al, 1997). Antibodies
specific for proliferating cell nuclear antigen (PCNA; PC10) and
Ki67 were obtained from Dako (Denmark). 
Tissues 
A range of normal tissues (tonsil, spleen, lymphoid node, thymus,
skin, pancreas, testis, colon, kidney, liver, brain and lung) were
obtained from the Cellular Pathology Department at the John
Radcliffe Hospital, Oxford, UK. Tumour samples from several
organ sites were obtained from the frozen tissue bank in the same
University Department. The diagnosis was reviewed and
confirmed in each case. Cryostat sections of 8 mm were prepared
and mounted on poly-L-lysine coated multi-well microscope slides
(C. A. Hendley-Essex Ltd, Loughton, Essex, England.) After
overnight drying, slides were processed for immunostaining
immediately or stored at –20°C until required. 
Immunohistochemistry 
Slides were fixed for 10 min in 4% formaldehyde in phosphate-
buffered saline. Endogenous peroxidase activity in the samples
was blocked for 5 min in Peroxidase Block (Dako K4007) before
rinsing in distilled water and washing in PBS. Primary antibodies
were then applied to the slides for 90 min at the following concen-
trations: BFL-103, undiluted tissue culture supernatant from
hybridoma cultures; Ki67 (10 mg ml–1); PC10 (1 mg ml–1). For
BFL-103, the secondary antibody used was an Envision Mouse kit
(1:200 dilution, Dako K4006). For the Ki67 and PC10 samples,
the secondary was a goat anti-mouse HRP conjugate (1:200; Dako
PO447). All secondary antibodies were applied for 30 min at room
temperature. Slides were counterstained with haematoxylin before
mounting in Aquamount (BDH). Substitution of the primary anti-
body with PBS was used as a negative control 
RESULTS 
Characterization of a BLM-specific monoclonal
antibody 
The generation of the BFL-103 anti-BLM mouse monoclonal anti-
body has been described previously (Wu et al, 2000a). BFL-103
was raised in Balb-C mice following injection of purified, recom-
binant BLM protein. BFL-103 recognizes full-length recombinant
BLM using Western blotting, as well as a recombinant fragment
representing residues 1–447 of BLM, indicating that the BFL-103
epitope lies in the N-terminal domain of the 1417 amino acid BLM
protein. BFL-103 was shown to be specific for BLM by demon-
strating a lack of staining of GMO8505 cells isolated from an
individual with BS and shown to lack expression of the BLM
protein (Wu et al, 2000a). 
Normal tissue distribution of the BLM protein 
In all tissues examined, where seen, BLM protein expression was
confined to cell nuclei. In normal tissues, no positive staining with
the BFL-103 antibody was observed (Figure 1 shows kidney as an
example) except in areas where cell proliferation is ongoing. There
was high expression in thymic cortex, lymphoid follicles of the
tonsil, and around the periarteriolar lymphoid sheath of the spleen.
Scattered staining for BLM was also evident in cells from the
medulla of the thymus, the cortex and paracortex of the tonsil, 
the red pulp of the spleen, the placenta, and the basal layers of the
skin. These are the areas of cell proliferation in these tissues. 
Expression of the BLM protein in tumour tissues 
Positive staining for BLM was observed in tumours of both
lymphoid and epithelial origin (Figure 1; Tables 1 and 2).
Generally, 5–50% of cells in each tumour sample stained positive
for BLM using BFL-103, but in rare cases more than 60% of cells
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Table 1 Summary of staining for BLM in tumour tissues 
Tumour type No of cases Nuclear positive (%) 
Breast cancers  <5 5–30 30–60 >60
Grade I 1 – 1 – – 
Grade 2 3 – 3 – – 
Grade 3 5 1 4 – – 
Lymphomas 
Follicular lymphoma 6 – 6 – – 
Large B cell lymphoma 5 – 2 3 – 
Anaplastic large cell 4 – 3 1 – 
T cell lymphomas 5 – 3 1 1 
Kidney carcinoma 5 3 – 2 – 
Lung cancers 
Small cell carcinoma 4 – 1 1 2 
Squamous cell carcinoma 4 – 3 1 – 
Adenocarcinoma 4 – 3 1 – 
Colon cancer 4 – 3 1 – 
Tumours are classified both by type and by the percentage of nuclei showing positive
staining with BFL-103. expressed detectable levels of BLM (Tables 1 and 2). There was a
good correlation between the expression of BLM and that of 2
independent, well-established markers of proliferation; PCNA and
Ki67 (Table 2). In general, the percentage of cells scoring positive
for BLM expression was equal to or a little below the equivalent
percentage values for PCNA and Ki67. 
DISCUSSION 
We have conducted a detailed analysis of the distribution and
expression of the BLM protein in normal and neoplastic human
tissues using a specific monoclonal antibody. We have shown that
BLM is expressed in only a limited range of normal tissues, such
as in lymphoid tissue, and in the skin and digestive tract, with a
pattern of expression indicative of BLM being a marker of cellular
proliferation. Consistent with this finding, BLM was shown to be
widely expressed in tumours of both lymphoid and epithelial
origin. In the range of tumours that we studied, the percentage of
cells expressing BLM was very similar to the equivalent values for
two established proliferation markers, PCNA and Ki67. The
slightly lower percentage values for BLM probably reflects the
fact that the intensity of staining using the BFL-103 anti-BLM
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Figure 1 Staining of human normal and tumour tissues using the anti-BLM specific antibody, BFL-103. Panels A–D represent normal tissues, and panels E–H
represent tumour tissue. Panels: A, kidney; B, placenta; C, tonsil, showing positive nuclei mainly in the germinal centre; D, thymus, showing extensive, but
scattered positive nuclei; E, lymphoma of a large B-cell type; F, an example of a breast carcinoma, showing a high level of nuclear staining; G and H depict the
same breast carcinoma sample stained with the BFL-103 and Ki67 antibodies, respectively. Note that a similar percentage of nuclei are stained positive in each
case in panels G and H antibody was consistently somewhat weaker than that seen when
using the PC-10 or Ki67 antibodies. 
BLM is defective in BS, a rare disorder which is associated with
several phenotypic abnormalities. Of greatest relevance to the
findings of this study, is the fact that BS individuals are cancer
prone and, more particularly, succumb at an early age to cancers of
all (or nearly all) types, including leukaemias, lymphomas and
epithelial tumours (German, 1993, 1995). There is the possibility,
therefore, that the BLM gene will be defective in a proportion of
tumours that arise sporadically in the general population.
Although we have not addressed this question directly, it might
have been expected that we would have detected loss of BLM
staining in some of the tumour samples if BLM expression was
lost in a high percentage of any of the tumour types studied.
However, we did not obtain any evidence of loss of BLM expres-
sion in these tumour samples and therefore we would tentatively
conclude that loss of BLM expression does not occur at a high
frequency in any of the tumour types studied here. This does not
exclude the possibility that mechanisms of BLM inactivation other
than loss of BLM protein expression will be found in a significant
number of sporadic cancers in humans. 
BLM is much more widely expressed in human tumours than in
normal tissues, particularly those of epithelial origin. This presum-
ably reflects the far greater fraction of proliferating cells that exists
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Table 2 Results of staining a variety of neoplastic tissues with BFL 103, compared with staining for two
proliferation markers, PC10 (for PCNA) and Ki67 
Tissue Diagnosis BFL103 PC10 Ki67 
Kidney Renal cell carcinoma 0 0 0 
Kidney Renal cell carcinoma <50 <50 <50 
Kidney Renal cell carcinoma 0 <1 <1 
Kidney Seminoma 50 50 50 
Kidney Wilms <1 <1 <1 
Lung Small Cell Carcinoma 40 60 60 
Lung Small Cell Carcinoma 70 70 70 
Lung Small Cell Carcinoma 70 70 70 
Lung Small Cell Carcinoma 30 30 30 
Lung Squamous Cell Carcinoma 30–40 30 30 
Lung Squamous Cell Carcinoma 30 30 25 
Lung Squamous Cell Carcinoma 15 15 15 
Lung Squamous Cell Carcinoma 10 10 10 
Lung Mixed adeno &SQC 0 <1 <1 
Lung Adenocarcinoma 20 20 20 
Lung Adenocarcinoma 30 30 30 
Lung Adenocarcinoma 15–20 15 10 
Lung Papillary Adenocarcinoma <5 <5 <5 
Colon Adenocarcinoma 35 40 40 
Colon Adenocarcinoma 20 30 30 
Colon Adenocarcinoma 15 20 20 
Colon Adenocarcinoma 20 30 30 
Breast Adenocarcinoma 3–5 15–20 15–20 
Breast Adenocarcinoma – – – 
Breast Adenocarcinoma 3–5 5–15 5–10 
Breast Adenocarcinoma 5 5 5 
Breast Adenocarcinoma 10 25 25 
Breast Adenocarcinoma 5–10 15–20 15–20 
Breast Adenocarcinoma 15 15–20 15–20 
Breast Adenocarcinoma 10–15 10–15 10–15 
Breast Adenocarcinoma 3–7 5–10 5–10 
Lymph node Follicular Lymphoma <5 5–10 5–10 
Lymph node Follicular Lymphoma 1–5 10 10–15 
Lymph node Follicular Lymphoma 5 5–10 5–10 
Lymph node Follicular Lymphoma 10–15 15–20 15–20 
Lymph node Follicular Lymphoma 5 15–20 15–20 
Lymph node Follicular Lymphoma 5 5–10 5–10 
Lymph node Large B cell lymphoma 25 40 40 
Lymph node Large B cell lymphoma 25 35 40 
Lymph node Large B cell lymphoma 15 30 30 
Lymph node Large B cell lymphoma 10 20–25 20–25 
Lymph node Large B cell lymphoma 5 25 25 
Lymph node T cell lymphoma 10–15 weak 25–30 20–25 
Lymph node T cell lymphoma 15–20 weak 20 15 
Lymph node T cell lymphoma 10 weak 22 20 
Lymph node T cell lymphoma 40
Lymph node T cell lymphoma 5–10 25 40 
Lymph node T cell lymphoma 20 20–30 20–30 
Lymph node T cell lymphoma 15 25 25 
Lymph node T cell lymphoma 35 80 80 
Lymph node T cell lymphoma 10 15 15 
Testis T cell lymphoma 20 weak 55 45 in tumours than in normal tissues of the same origin. As with other
proliferation markers of this sort there is the possibility that BLM
might be considered a suitable target for the development of anti-
tumour strategies aimed at the elimination of proliferating tumour
cells. Moreover, measurement of BLM expression could have
some utility in cancer prognosis. Clearly, further work is required
to obtain additional evidence that there is any validity to these
suggestions. 
In summary, we have developed a BLM-specific antibody that is
suitable for use in immunohistochemical analysis of human
tissues, including primary human tumours. We have shown that
the expression of BLM is restricted to the proliferating compart-
ment of normal human tissues, but is widely expressed in tumour
tissue of both lymphoid and epithelial origin. BLM is apparently
localized exclusively to the nucleus in vivo. With the development
of BFL-103, we now have the capability to analyse BLM expres-
sion more generally in tumour biopsy material to ascertain whether
alterations/abnormalities in BLM expression occur at a measurable
frequency in human tumours both before and after antitumour
therapy. 
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